Rifampicin-warfarin co-administration requires individualized management rather than fixed dose adjustment strategies, with frequent INR monitoring, timely dose modification, and pharmacist involvement facilitating safe maintenance of anticoagulation during this clinically significant drug-drug interaction.
Key Findings
Results
Rifampicin initiation caused a approximately 200% increase in warfarin dose requirement in a patient with chronic thromboembolic pulmonary hypertension.
The patient's warfarin dose increased from 1.5 mg/day to 4.5 mg/day after rifampicin-containing antituberculosis treatment was started.
The patient was a 64-year-old Chinese male requiring long-term warfarin therapy for chronic thromboembolic pulmonary hypertension.
Rifampicin is a potent inducer of cytochrome P450 enzymes, which substantially reduces warfarin efficacy.
The dose increase represents a tripling of the original warfarin dose.
Results
A therapeutic INR range of 2–3 was achieved after approximately 2 months of structured monitoring and dose adjustment during rifampicin co-administration.
INR was monitored twice weekly during the initial phase of rifampicin co-administration.
Monitoring frequency was subsequently reduced to weekly until INR stabilization was achieved.
Stabilization within the therapeutic range (INR 2–3) occurred after approximately 2 months.
No thromboembolic events or major bleeding complications were reported during this period.
Results
A pharmacist-supported structured monitoring approach was applied and associated with safe anticoagulation management during rifampicin co-administration.
Pharmacist-led management was described as a key component of the clinical management strategy.
The approach included structured INR monitoring, timely dose modification, and individualized rather than fixed dose adjustment strategies.
The clinical course, INR values, warfarin dose adjustments, and safety outcomes were retrospectively reviewed.
The authors concluded that pharmacist involvement 'may facilitate safe maintenance of anticoagulation during this clinically significant drug-drug interaction.'
Conclusions
The authors concluded that individualized rather than fixed dose adjustment strategies are necessary for warfarin management during rifampicin therapy.
The paper emphasizes that warfarin management is challenging due to drug-drug interactions and individual variability.
The authors state that 'rifampicin-warfarin co-administration requires individualized management rather than fixed dose adjustment strategies.'
The case is presented as illustrative of the need for structured, personalized anticoagulation monitoring protocols.
The report highlights that structured pharmacist-supported monitoring was applied as a practical management framework.
What This Means
This research describes the case of a 64-year-old man in China who was taking warfarin (a blood thinner) to treat a serious lung blood vessel condition, and then needed to start rifampicin, an antibiotic used to treat tuberculosis. Rifampicin is known to make the liver break down warfarin much faster than normal, which can cause the blood thinner to stop working effectively, raising the risk of dangerous blood clots. The clinical team, with pharmacist involvement, closely monitored the patient's blood clotting levels (measured by a test called INR) and progressively increased his warfarin dose from 1.5 mg per day to 4.5 mg per day — a tripling of the original dose — to keep his anticoagulation in the safe and effective range.
After about two months of frequent monitoring (twice weekly at first, then weekly), the patient's INR stabilized in the target range of 2–3, and he experienced no blood clots or significant bleeding during this period. The monitoring schedule and dose adjustments were managed on an individualized basis rather than following a one-size-fits-all protocol, which the authors suggest was key to the safe outcome.
This research suggests that when patients need to take both warfarin and rifampicin at the same time, the interaction between these drugs can be dramatic and unpredictable, requiring close, frequent blood testing and active involvement of pharmacists and clinicians to adjust doses appropriately. A fixed or standard dose increase is unlikely to be sufficient for all patients, and individualized monitoring strategies may be important for preventing both clotting and bleeding complications in this situation.
Li X, Wu L, Liu X, Li P, Zhao L. (2026). Warfarin Dose Adjustment During Rifampicin Therapy: A Case Report with Practical Monitoring Implications.. Journal of visualized experiments : JoVE. https://doi.org/10.3791/73270